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Abstract
Objectives
There are significant geographical differences in the prevalence and incidence of celiac dis-
ease that cannot be explained by HLA alone. More than 40 loci outside of the HLA region
have been associated with celiac disease. We investigated the roles of these non-HLA
genes in the development of tissue transglutaminase autoantibodies (tTGA) and celiac dis-
ease in a large international prospective cohort study.
Methods
A total of 424,788 newborns from the US and European general populations and first-
degree relatives with type 1 diabetes were screened for specific HLA genotypes. Of these,
21,589 carried 1 of the 9 HLA genotypes associated with increased risk for type 1 diabetes
and celiac disease; we followed 8676 of the children in a 15 y prospective follow-up study.
Genotype analyses were performed on 6010 children using the Illumina ImmunoChip. Lev-
els of tTGA were measured in serum samples using radio-ligand binding assays; diagnoses
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of celiac disease were made based on persistent detection of tTGA and biopsy analysis.
Data were analyzed using Cox proportional hazards analyses.
Results
We found 54 single-nucleotide polymorphisms (SNPs) in 5 genes associated with celiac
disease (TAGAP, IL18R1, RGS21, PLEK, and CCR9) in time to celiac disease analyses
(10−4>P>5.8x10−6). The hazard ratios (HR) for the SNPs with the smallest P values in
each region were 1.59, 1.45, 2.23, 2.64, and 1.40, respectively. Outside of regions previ-
ously associated with celiac disease, we identified 10 SNPs in 8 regions that could also
be associated with the disease (P<10−4). A SNP near PKIA (rs117128341, P = 6.5x10−8,
HR = 2.8) and a SNP near PFKFB3 (rs117139146, P<2.8x10−7, HR = 4.9) reached the
genome-wide association threshold in subjects from Sweden. Analyses of time to detec-
tion of tTGA identified 29 SNPs in 2 regions previously associated with celiac disease
(CTLA4, P = 1.3x10−6, HR = 0.76 and LPP, P = 2.8x10−5, HR = .80) and 6 SNPs in 5
regions not previously associated with celiac disease (P<10−4); non-HLA genes are there-
fore involved in development of tTGA.
Conclusions
In conclusion, using a genetic analysis of a large international cohort of children, we associ-
ated celiac disease development with 5 non-HLA regions previously associated with the dis-
ease and 8 regions not previously associated with celiac disease. We identified 5 regions
associated with development of tTGA. Two loci associated with celiac disease progression
reached a genome-wide association threshold in subjects from Sweden.
Introduction
Celiac disease is strongly associated with the human leukocyte antigen (HLA) DR3–DQ2.5 (i.
e., DRB103-DQA105:01-DQB102:01) or DR4-DQ8 (DRB104-DQA103-DQB103:02)
haplotypes on chromosome 6 [1]. Moreover, there is an HLA gene-dose effect on the disease
risk as individuals carrying two copies of DR3-DQ2.5 are at a higher susceptibility for celiac
disease than those with only one copy [2,3]. Although carrying either DR3–DQ2.5 or DR4–
DQ8 is almost a necessity to develop celiac disease, these haplotypes are common in the general
population and not all carriers develop clinical disease [4]. Since the first genome-wide case/
control association study (GWAS) on celiac disease was published in 2007, a total of 40 non-
HLA loci have been suggested as being associated with celiac disease[5–9]. A significant pro-
portion of the genetic predisposition comes from the HLA region (odds ratio of>5) while
non-HLA genes have modest effect sizes with an odds ratio between 1.12 and 1.36 for celiac
disease [10]. The role of these non-HLA genes have not been assessed in those with early onset
celiac disease, particularly using a prospective cohort.
Celiac disease is increasing in frequency, with significant intra- and inter-country differ-
ences in the prevalence and incidence of the disease[11]. Despite recent advances in celiac dis-
ease genetics, it remains elusive why some, but not all, individuals with the HLA risk genotypes
develop celiac disease. Although the ingestion of gluten is required to trigger and maintain
celiac disease, gluten exposure is nearly universal. Therefore, exposures to other environmental
factors may also be important in the pathogenesis. Celiac disease is likely a multifactorial disor-
der where multiple genes and multiple environmental factors interact in a complex manner.
Celiac Disease Genes
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Disease risk genes may act at various stages of autoimmunity progression, with some genes
playing a role early in autoantibody development, and others playing a critical role in the later
stages of celiac disease development. This stage-specific contribution of different genes to the
celiac disease risk is an important concept, which cannot be investigated using the cross-sec-
tional case/control study design employed in all previous studies. Furthermore, genetic factors
responsible for the development of tissue transglutaminase autoantibodies (tTGA) and ethnic-
or country-specific differences in a genetically predisposed population have not been reported
previously.
The Environmental Determinants of Diabetes in the Young (TEDDY) is an international
multicenter study that screened over 420,000 newborns from the general population in four
different countries to identify children with high risk HLA genes for the development of type 1
diabetes (T1D) [12]. Recently, TEDDY demonstrated the impact of different HLA genotypes
on the risk of celiac disease as well as tTGA development, and furthermore confirmed that the
HLA-DR3-DQ2/DR3-DQ2 genotype confers the single highest genetic risk for the disease dur-
ing early childhood[13]. We also found differences in risk of disease between the participating
countries that could not be explained by HLA-DR-DQ, suggesting that the risk may be influ-
enced by variations in the environment and/or involvement of genes outside the HLA-DR-DQ
region. One such recent finding from the TEDDY study was the protective association of
HLA-DRB10401 with celiac disease autoimmunity[14].
The present study genotyped 195,806 SNPs on ImmunoChip in 6,010 TEDDY children to
identify potential genetic factors responsible for the development of early autoimmunity (tTGA
development) and celiac disease as well as country-specific differences in genetic predisposition.
Results
A total of 703 subjects developed persistent tTGA and were considered “events” in the Cox
proportional hazards models for persistent tTGA. Only 317 of these 703 persistently tTGA
positive children received an intestinal biopsy and 262 of the 317 subjects were confirmed to
have celiac disease at the time the procedure was performed. Eleven children with positive
tTGA tests at the initial time point were biopsied before they could be confirmed as having per-
sistent tTGA and eight of them also had biopsy-proven celiac disease. Eighteen other children
who had persistent tTGA levels>100 units but did not have a biopsy were also considered to
have celiac disease for purposes of the study. Therefore, 288 subjects were considered as
“events” in the analysis of the time-to-celiac disease. There are known differences based upon
the family history of celiac disease, HLA-DR-DQ genotype, gender, HLA-DPB1 and country of
residence. These factors were adjusted in the Cox proportional hazard models.
Analysis of reported celiac disease SNPs
A total of 69 SNPs were previously reported to be associated with celiac disease based on the
NHGRI GWAS Catalog[5,7,15–17], of which 48 were represented on the ImmunoChip (S4
Table). Risk Variants that have been reported but are not on the ImmunoChip are listed in S6
Table. In the time-to-celiac disease analysis, only one SNP (rs13015714/IL18R on 2q12.1,
HR = 1.42, p = 1.38x10-4) attained significance after Bonferroni correction (p = 0.05/48=0.001).
Several other SNPs were close to the significance threshold of 0.001 or had p-value<0.05:
rs653178/SH2B3 (HR = 1.30; p = 0.002); rs1464510/LPP (HR = 1.28; p = 0.002); rs17035378/
PLEK (HR = 0.75; p = 0.004); rs6806528/FRMD4B (HR = 1.44; p = 0.004); rs11221332/ETS1
(HR = 1.29; p = 0.006); rs2298428/YDJC (HR = 1.27; p = 0.012); rs2327832/TNFAIP3 (HR = 1.24;
p = 0.025); rs802734/PTPRK (HR = 1.21; p = 0.034); rs13098911/CCR9 (HR = 1.29; p = 0.041);
and rs10876993/CDK4 (HR = 0.84; p = 0.042).
Celiac Disease Genes
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For time-to-persistent tTGA analysis, we observed 10 SNPs with p<0.05: rs1464510/LPP
(HR = 1.16; p = 0.004); rs2298428/YDJC (HR = 1.17; p = 0.011); rs864537/CD247 (HR = 0.87;
p = 0.013); rs13015714/IL18R1 (HR = 1.15; p = 0.02); rs10936599/MYNN (HR = 1.15; p = 0.022);
rs11203203/UBASH3A (HR = 1.13; p = 0.027); rs11712165/CD80 (HR = 1.12; p = 0.035); rs7574
865/STAT4 (HR = 1.14; p = 0.036); rs2816316/RGS1 (HR = 0.859; p = 0.038); and rs802734/PTP
RK (HR = 1.12; p = 0.046).
Analysis of previously reported celiac disease regions
Next, we extended our analysis to all SNPs within 400 kb up- and downstream of the 48
reported SNPs. The–log10 p-values for all SNPs in these regions are plotted in Fig 1A for
tTGA and Fig 1B for celiac disease. Since these are analyses for candidate regions, we consid-
ered p<10−4 as suggestive evidence for confirmation because multiple SNPs are tested in each
region and the SNPs are in high linkage disequilibrium.
In the tTGA plots, the two regions with strongest evidence were CTLA4 and LPP (S1 Fig). The
SNPs with smallest p-value in these two regions are: rs12990970/CTLA4 (HR = 0.76; p = 1.3x10-6)
and rs11709472/LPP (HR = 0.80; P = 2.8x10-5) (Table 1). It is important to note that in our study,
the presence of the minor allele of rs12990970/CTLA4 is protective (HR<1). In contrast, earlier
studies have shown that CTLA4 (rs4675374-A) is a risk factor for celiac disease (OR = 1.14)[5,18].
The Kaplan-Meier plots for the three SNPs with smallest p-values in time-to-tTGA analysis
(rs12990970/CTLA4; rs11709472/LPP; rs2925499/TNFRSF14) are shown in Fig 1C.
In the celiac disease analysis, we found 5 regions (TAGAP, IL18R1, RGS21, PLEK, and CCR9)
with SNPs that had p-values<10−4: rs1054091/TAGAP (HR = 1.59; p = 5.8x10-6); rs4851575/
IL18R1 (HR = 1.45; p = 5.7x10-5); rs1936670/RGS21 (HR = 2.23; p = 5.1x10-5); rs114569351/
PLEK (HR = 2.64; p = 4.2x10-5); and rs12493471/CCR9 (HR = 1.40; p = 6.4x10-5) (Table 1, S2
Fig). The Kaplan-Meier plots of three SNPs with smallest p-values in the time-to-celiac disease
analysis (rs1936670/RGS21, rs12493471/CCR9, rs1054091/TAGAP) are shown in Fig 1D.
SNPs associated with progression to persistent tTGA outside of the
known celiac disease regions
We then extended the analysis to include all SNPs genotyped on the ImmunoChip in search
of novel SNP associations. For these analyses, 133,620 with minor allele frequencies of at
least 0.01 were tested and therefore the statistical significance for any single SNP requires a
Bonferroni-corrected p<3.7x10-7. In the time-to-persistent tTGA analyses, none of the
SNPs reached this significance threshold, but 7 SNPs were identified in 5 novel celiac
disease regions with p<10−4: rs117561283/IFNG (HR = 1.81; p = 2.1x10-5); rs8013918/FOS
(HR = 0.80; p = 4.9x10-5); rs2409747/XKR6 (HR = 1.37; p = 5.4x10-5); rs114157400/BANK1
(HR = 1.62; p = 8.4x10-5); and rs72717025/FCGR2A (HR = 1.84; p = 9.6x10-5) (Fig 2A;
Table 2). These SNPs are novel candidate SNPs with suggestive evidence and require further
confirmation studies to rule out false positive discoveries. The Kaplan-Meier plots of three
SNPs (rs2409747/XKR6, rs117561283/IFNG, and rs8013918/FOS discovered in time-to-
tTGA analysis are shown in Fig 2C.
SNPs associated with progression to celiac disease outside of the
known celiac disease regions
In a similar analysis using time-to-celiac disease with all SNPs, no SNP reached the Bonfer-
roni-corrected p<3.7x10-7 significance threshold but 10 SNPs outside of the known celiac dis-
ease regions reached the suggestive threshold (p<10−4) (Fig 2B). These SNPs mapped to 8
Celiac Disease Genes
PLOS ONE | DOI:10.1371/journal.pone.0152476 March 25, 2016 4 / 20
Fig 1. SNPs in the previously reported celiac disease associated regions.Manhattan plot of P-values on the −log10 scale for SNPs (±400kb) previously
associated with celiac disease (A) and persistent tissue transglutaminase autoantibody (tTGA) positivity (B). HRs and p-values are calculated using three
possible genotypes and adjusted for family history of celiac disease, HLA-DR-DQ genotype, gender,HLA-DPB1, population stratification (ancestral
Celiac Disease Genes
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different regions: rs11739460/TCOF1 (HR = 1.41; p = 2.9x10-5); rs77532435/GRB10 (HR =
2.05; p = 4.8x10-5); rs13014907/ZNF804A (HR = 2.46; p = 6.0x10-5); rs72704176/ASH1L
(HR = 2.26; p = 7.4x10-5); rs3771689/BAZ2B (HR = 0.56; p = 9.3x10-5); rs2409747/XKR6
(HR = 1.58; p = 9.3x10-5); rs6967298/AUTS2 (HR = 0.61; p = 9.4x10-5); and rs61751041/
LAMB1 (HR = 2.23; p = 9.8 x10-5) (Table 2). The Kaplan-Meier plots of three novel SNPs
(rs13014907/ZNF804A, rs11739460/TCOF1, and rs77532435/GRB10 discovered in time-to-
celiac disease analysis are shown in Fig 2D.
Country-specific genetic factors associated with progression to celiac
disease
To explore country-specific genetic factors, the data with all 133,620 SNPs were analysed for
each country. In the analysis of celiac disease risk among the Swedish participants, SNPs
reached the Bonferroni-corrected p<3.7x10-7 significance threshold in two regions: 8q21.1 and
10p15 (Fig 3). The SNP with the smallest p-value in the 8q21.1 region was rs117128341
(p = 6.52x10-8, HR = 2.78, MAF = 0.04), a SNP in the intragenic region of the protein kinase
inhibitor alpha (PKIA) gene. The other two nearby genes in this region are ZC2HC1A and IL7.
The SNP with the smallest p-value in the chromosome 10p15 region was rs117139146
(p = 2.78x10-7, HR = 4.85, MAF = 0.014). A nearby gene in this region is PFKFB3, which was
previously shown to be associated with celiac disease. Five SNPs with p<10−4 map to the PKIA
region, and one SNP maps to the PFKFB3 region (Table 3). In the separate analyses of two
other countries, the US and Finland, none of the six SNPs reached the significance threshold.
The analysis in Germany was not conducted due to small sample size. Kaplan-Meier plots of
these six SNPs for different countries (Fig 4) clearly indicated country-specific differences. The
associations of these six SNPs with celiac disease in Sweden and the other three countries are
listed in Table 3. There was no evidence of difference between US and Finland, therefore we
combined US, Finland and Germany together to compare with Sweden in the analysis of inter-
action. A Cox proportional hazards model with an interaction term of the SNP with country
heterogeneity) and country of residence (as strata). The red dashed line represents p = 1x10−4. Kaplan-Meier plots of the three most significant SNPs
associated with celiac disease (C) and tTGA (D) are plotted by dividing the subjects in two groups: (i) Major homozygous (black curves) and (ii) Heterozygous
combined with minor homozygous (red curves).
doi:10.1371/journal.pone.0152476.g001
Table 1. Associations with celiac disease or tissue transglutaminase autoantibody (tTGA) positivity (p<10−4), mapped to previously known
regions.
SNPa CHR BP MAF HR CD P-valueb CD HR tTGA P-valueb tTGA # SNPS (P<10−4) Nearby Gene
rs1936670 1 190598185 0.02 2.23 5.10x10-5 1.36 0.038 1 RGS21
rs4851575 2 102391635 0.24 1.45 5.69x10-5 1.16 0.014 49 IL18R1, IL18RAP
rs114569351 2 68520426 0.02 2.64 4.19x10-5 1.73 0.002 1 PLEK,FBXO48
rs12493471 3 45926682 0.36 1.40 6.36x10-5 1.09 0.098 1 CCR9,LZTFL1,CXCR6
rs1054091 6 159389500 0.17 1.59 5.81x10-6 1.22 0.004 2 RSPH3,TAGAP
rs12990970 2 204408934 0.38 0.82 0.027 0.76 1.26x10-6 21 NPM1P33,CTLA4
rs11709472 3 189560280 0.45 0.82 0.019 0.80 2.75x10-5 8 LPP
CHR: Chromosome; BP: Base Pair Position (NCBI 36.3); MAF: Minor Allele Frequency; HRCD: Hazard Ratio in celiac disease analysis; HRtTGA: Hazard
Ratio in tTGA analysis. P-values < 10−4 are highlighted in bold
aThe data for the SNP with smallest p-value is presented from each region.
bHRs and p-value adjusted for family history of celiac disease, HLA-DR-DQ genotype, gender, HLA-DPB1, population stratiﬁcation (ancestral
heterogeneity) and country of residence (as strata).
doi:10.1371/journal.pone.0152476.t001
Celiac Disease Genes
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Fig 2. Associations with risk of celiac disease and risk of persistent tissue transglutaminase autoantibody (tTGA) positivity.Manhattan plot of
133,620 SNPs with MAF>0.01, displaying the P-values on the −log10 scale for SNP associations with celiac disease (A) and persistent tTGA positivity (B).
HRs and p-values are calculated using three possible genotypes and adjusted for family history of celiac disease, HLA-DR-DQ genotype, gender,
HLA-DPB1, population stratification (ancestral heterogeneity) and country of residence (as strata). The red dashed line represents p = 1x10−4, the red solid
Celiac Disease Genes
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was used to compare the effects of these six SNPs between Sweden and other countries, adjust-
ing for country (Sweden vs other), gender, HLA-DPB1 genotype, HLA-DR-DQ genotype, fam-
ily history of celiac disease, and population stratification. The analysis shows that the effect of
any of these SNPs in Sweden is statistically different (p<0.05) from the effect in the other coun-
tries (rs73687528: p<0.001; rs117128341: p<0.001; rs79215674: p = 0.002; rs74450608:
p = 0.029; rs79374792: p<0.001; rs117139146: p = 0.001).
Country-specific associations with progression to tTGA
In time-to-persistent tTGA analysis among subjects from Sweden, none of the SNPs reached
the Bonferroni-corrected p<3.7x10-7 significance threshold, however, 9 SNPs in 9 different
genomic regions had p<10−4 (S5 Table). One such SNP was rs117139146 in the region of
PFKFB3 (p = 7.34x10-5, HR = 2.79, MAF = 0.014).
Discussion
HLA-DR3-DQ2.5 and DR4-DQ8 are known as the most important genetic risk factors for
celiac disease; however, these two haplotypes only account for part of the genetic risk. Recently,
we demonstrated that HLA can be used to assess the risk of celiac disease using the large pro-
spective TEDDY cohort [13]. This previous study clearly demonstrated an HLA gene dose
effect of HLA-DR3-DQ2.5 on the risk of celiac disease autoimmunity was doubled among het-
erozygotes (HR = 2.09) but was a near 6-fold increased among homozygotes (HR = 5.70) as
compared to children carrying the lowest-risk genotype DR4-DQ8 [13]. However, another
finding of importance from this study was the difference in incidence of celiac disease between
the participating countries which could not be attributed to HLA suggesting that
line represents Bonferroni correction threshold. Kaplan-Meier plots of selected SNPs associated with celiac disease (C) and persistent tTGA (D) are plotted
by dividing the subjects in two groups: (i) Major homozygous (black curves) and (ii) Heterozygous combined with minor homozygous (red curves).
doi:10.1371/journal.pone.0152476.g002
Table 2. Novel associations with celiac disease or tissue transglutaminase autoantibody (tTGA) positivity (p<10−4).
SNPa CHR BP MAF HR CD P-valueb CD HR tTGA P-valueb tTGA # SNPS (P<10−4) Nearby Gene
rs72704176 1 153692482 0.02 2.26 7.42x10-5 1.31 0.085 1 ASH1L
rs3771689 2 159930048 0.14 0.56 9.27x10-5 0.85 0.037 2 BAZ2B
rs13014907 2 185781851 0.01 2.46 5.99x10-5 1.45 0.050 1 ZNF804A
rs11739460 5 149685099 0.40 1.41 2.88x10-5 1.05 0.319 2 TCOF1
rs77532435 7 50641412 0.03 2.05 4.82x10-5 1.38 0.015 1 GRB10
rs6967298 7 69652445 0.19 0.61 9.42x10-5 0.90 0.137 1 AUTS2
rs61751041 7 107381421 0.02 2.23 9.76x10-5 1.61 0.002 1 LAMB1
rs72717025 1 159736883 0.02 1.41 0.207 1.84 9.61x10-5 1 FCGR2A
rs114157400 4 103154484 0.04 1.71 0.003 1.62 8.43x10-5 2 BANK1
rs2409747 8 11115872 0.11 1.58 9.28x10-5 1.37 5.37x10-5 1 XKR6
rs117561283 12 66732860 0.03 1.96 0.002 1.81 2.14x10-5 1 IFNG
rs8013918 14 74779319 0.45 0.85 0.066 0.80 4.91x10-5 1 FOS
CHR: Chromosome; BP: Base Pair Position (NCBI 36.3); MAF: Minor Allele Frequency; HRCD: Hazard Ratio in celiac disease analysis; HRtTGA: Hazard
Ratio in tTGA analysis. P-values < 10−4 are highlighted in bold
aThe data for the SNP with smallest p-value is presented from each region.
bHRs and p-value adjusted for family history of celiac disease, HLA-DR-DQ genotype, gender, HLA-DPB1, population stratiﬁcation (ancestral
heterogeneity) and country of residence (as strata).
doi:10.1371/journal.pone.0152476.t002
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environmental factors or other genes could contribute to the disease risk. In the current study,
we used the same cohort to assess the association of non-HLA genes to the progression to
tTGA in addition to progression to celiac disease in early childhood. A strength of this study
Fig 3. Associations with risk of celiac disease in the Swedish population. A:Manhattan plot of 133620
SNPs with MAF>0.01, displaying the P-values on the −log10 scale for the SNPs associated with celiac
disease in the Swedish TEDDY population. B: Regional association plots at the PKIA locus generated by
LocusZoom, showing the significance of association and the recombination rate. Colors represent HapMap
CEU linkage disequilibrium r2 values with the most significantly associated SNP (rs117128341; shown in
purple).C: Pairwise LD plot for five SNPs in the region of PKIA. The five most significant SNPs from this
region are in high LD with each other.
doi:10.1371/journal.pone.0152476.g003
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includes the prospective nature of the study cohort that time-to-events analyses can be con-
ducted, looking specifically in this case for genetic factors that could be related to the early
development of celiac disease. Genetic studies have been traditionally done using cross-sec-
tional case/control study design, with populations of individuals with celiac disease who have
an unknown age of actual onset of autoimmunity. We know that the rate of seroconversion
and subsequent development of celiac disease is high in childhood, and suspect that the yearly
incidence slows down some time in adulthood. It is therefore possible that the genes involved
in early onset celiac disease may be different from those involved in adult (or late) onset celiac
disease. However, it may not be feasible to perform a prospective cohort study in at-risk adults
due to the presumed decline in incidence.
In the first stage of analyses, we only considered the 48 SNPs previously reported to be asso-
ciated with celiac disease and only one SNP was significant after Bonferroni correction. How-
ever, confirmatory evidence (p<10−4) was found for SNPs in five regions previously reported
to be associated with celiac disease (TAGAP, IL18R1, RGS21, PLEK, and CCR9). The HRs esti-
mated in this prospective cohort (HR = 1.40–2.64) are generally much higher than the odds
ratios (OR) estimated in the case control studies (OR = 1.12–1.36). The TAGAP gene encodes a
member of the Rho GTPase-activator protein superfamily involved in T cell activation and co-
regulation with IL-2, which has been previously associated with several autoimmune diseases,
including rheumatoid arthritis [19], celiac disease [20], and multiple sclerosis[21]. IL18R1 is
part of the cytokine receptor cluster on chromosome 2q12 which encodes for the receptors of
IL18; a cytokine involved in IFN-gamma synthesis and its mRNA expression is upregulated in
active patients with celiac disease [22]. Both genes play roles in the immune response and are
therefore rational candidates for conferring risk in an autoimmune disease such as celiac
disease.
The development of tTGA usually appears before the clinical onset of celiac disease and
often represents the earliest stage of autoimmunity, signifying a breakdown in tolerance. The
specificity of tTGA is high such that negative testing will almost certainly rule out celiac dis-
ease. However the positive predictive value of the antibody especially in screened cohorts is
Table 3. Six SNPs from two genomic regions significantly associated with celiac disease in Sweden. Five SNPs mapped to PKIA region and one
SNPmapped PFKFB3 region.
Sweden Other TEDDY
countries than
Swedenc
Sweden vs other TEDDY countriesc
SNP CHR BP MAF HRa pa HRa pa pb
rs73687528 8 79593304 0.064 2.27 5.09x10-6 0.69 0.209 <0.001
rs117128341 8 79612329 0.040 2.78 6.52x10-8 0.58 0.172 <0.001
rs79215674 8 79642439 0.027 2.94 4.69x10-7 0.32 0.098 0.002
rs74450608 8 79749568 0.016 3.10 1.70x10-5 0.64 0.532 0.029
rs79374792 8 79753034 0.040 2.76 7.11x10-7 0.60 0.208 <0.001
rs117139146 10 6240562 0.014 4.85 2.78x10-7 0.59 0.356 0.001
CHR: Chromosome; BP: Base Pair Position (NCBI 36.3); MAF: Minor Allele Frequency; HR: Hazard Ratio.
aHRs and p-value adjusted for family history of celiac disease, HLA-DR-DQ genotype, gender, HLA-DPB1 and population stratiﬁcation (ancestral
heterogeneity).
bP-value of testing the hypothesis that the effects of the SNP are the same between Sweden and other countries from a Cox model with adjustment for
family history of celiac disease, HLA-DR-DQ genotype, gender, HLA-DPB1, population stratiﬁcation (ancestral heterogeneity) and country of residence
(Sweden vs. other).
cOther participating countries of TEDDY are Germany, Finland and the US.
doi:10.1371/journal.pone.0152476.t003
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lower, between 70–83%[23], and some may even be transient[24]. Nevertheless, individuals
with only positive tTGA (even without evidence of villous atrophy) should not be disregarded.
Positive tTGA is an independent predictor of reduced bone mineral density[25], growth[26]
and mortality[27] and has been demonstrated to progress to celiac disease. In addition, many
individuals with positive celiac disease serology but normal villous morphology have been
shown to subsequently develop celiac disease in subsequent follow-up[28].
Although HLA genes are known to contribute to the development of tTGA, the contribu-
tion of non-HLA genes to the development tTGA and its role in early childhood celiac autoim-
munity is still not well characterized. This study suggests that there are a number of non-HLA
genes potentially implicated in the development of tTGA, and that there is overlap between
Fig 4. Country-specific associations with risk of celiac disease. Kaplan-Meier plots of five SNPs mapped to the PKIA region and one SNPmapped to the
PFKFB3 region, in the Swedish TEDDY population (A) and in the other TEDDY countries (B). Kaplan-Meier plots clearly indicate country-specific differences.
HRs and p-values are calculated using three possible genotypes and adjusted for family history of celiac disease, HLA-DR-DQ genotype, gender,
HLA-DPB1 and population stratification (ancestral heterogeneity).
doi:10.1371/journal.pone.0152476.g004
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genes involved in both tTGA and celiac disease development. For example, CTLA4 and LPP
are implicated in both celiac disease and tTGA development, although the association with
tTGA appears to be stronger than with celiac disease. On the other hand, association evidence
for RGS21, IL18R1, PLEK, CCR9, TAGAP was only found for celiac disease (Table 1).
Our recent studies on HLA class II genes in the TEDDY cohort also demonstrated that the
Swedish participants were at an increased risk for early celiac disease as compared to other par-
ticipating countries in TEDDY when adjusted for previously known risk factors[13]. We
hypothesized that this increased risk was due to variations in exposures to environmental fac-
tors. However, an alternative explanation is that there could be genetic differences outside of
the HLA-DR-DQ genes between Sweden and other countries which, in part, may account for
differences in disease incidences. The current study tested this hypothesis and found two
regions (chromosomes 8q21.1 and 10p15) with Bonferroni-corrected significance evidence in
the Swedish dataset, but not in the other three countries.
The chromosome 8q21.1 region is a novel genomic interval associated with celiac disease in
Sweden and contains five SNPs with strong evidence (1.7x10-5>p>6.5x10-8). It is near the
PKIA gene which encodes an extremely potent competitive inhibitor of cAMP-dependent pro-
tein kinase. It has been previously reported that intestinal PKIA gene expression was increased
among patients with untreated celiac disease [29]. Another study suggests a potential role of
cAMP-dependent protein kinase-A activation in the TNF-alpha production by gliadin-derived
peptides in intestinal epithelial cells [30].
One SNP (rs117139146) located in the intragenic region of chromosome 10p15 encoding
for PFKFB3 (6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3) was initially identified
as being associated with celiac disease through the 1000 Genomes Project using the Immuno-
Chip in 2012 [8]. The 440kB region between PFKFB3 and Protein Kinase C Theta (PRKCQ)
has been reported in a meta-analysis to identify rheumatoid arthritis (RA) risk loci in European
populations [31], and also has been shown to be associated with T1D [32]. In a meta-analysis
of Dutch and UK data sets, shared association with this PFKFB3/PRKCQ region was observed
in both RA and celiac disease [33]. In a study of North Americans, this region was suggestive of
an association with celiac disease, but did not reach significance[9].
Recently, two other studies have also shown region-specific associations observed in celiac
disease. The prevalence of tTGA and celiac disease is lower in Russian Karelia than in Finland,
which may be associated with a lower economic status and inferior hygienic environment.[34]
Also, discrepancy of celiac disease autoimmunity between Swedish and Danish T1D cohorts
suggests that regional variations in comorbidity of celiac disease in T1D is caused by difference
in exposure to environmental factors. [35]. Country-specific associations have also been
observed in other autoimmune diseases. For example, PADI4 was the first non-HLA genetic
risk factor known to be associated with RA, in a Japanese population[36]. However, in Spanish,
Swedish and UK populations, PADI4 polymorphisms were not associated with RA [37,38].
Gene-environment interactions probably are more important in diseases where the ingestion
of a particular type of food is required to maintain or trigger the disease. Recently, it has been
shown in Australia that infants of Asian-born parents are at increased risk of peanut allergy
compared to infants with parents migrating from other countries, suggesting gene-environ-
ment interactions are important in food allergy [39].
It is worth noting that our inference is based on a subset of SNPs included in the Illumina
ImmunoChip genotyping platform. Also, this analysis lacks power to confirm or discover
genetic factors with small effect size due to the limited number of events and short follow-up
time. None of the SNPs reached the Bonferroni-corrected significance threshold in the entire
dataset, although two regions reached the significance level in the Sweden population that has
a higher incidence rate of celiac disease. Analyses of the TEDDY cohort with longer follow-up
Celiac Disease Genes
PLOS ONE | DOI:10.1371/journal.pone.0152476 March 25, 2016 12 / 20
and more events will likely provide more robust evidence for the newly suggested and previ-
ously identified genetic factors. However, current age of our cohort allows the analysis of fac-
tors involved in the earliest development of celiac autoimmunity and celiac disease, which may
vary from celiac disease that develops in an older population. Our study also highlights the
necessity of having another large prospective cohort like TEDDY to fully elucidate the genetic
mechanism of celiac disease. It is also worth noting that the HRs presented in this analysis are
based on a population of children enriched for the high-risk celiac HLAs, and the findings may
not be generalizable to the general population. TEDDY is the largest and most intensive study
focusing on the genetic and environmental factors as well as gene-environment interactions for
diabetes and celiac disease [12]. The current study has not explored genetic factors in the con-
text of environmental exposure data and we believe that future integrated analyses of gene-
environment interactions will allow us to reveal the underlying molecular mechanism of the
disease.
Material and Methods
Material
A total of 424,788 newborns from both the general population and first-degree relatives with
T1D were screened for specific HLA genotypes. Of these, 21,589 had one of the nine HLA
genotypes associated with increased risk for T1D and celiac disease (S1 Table) and 8,676 eligi-
ble children were enrolled to a 15-year prospective follow-up[40] (Fig 5).
The Environmental Determinants of Diabetes in the Young (TEDDY) is a prospective
cohort study with the primary goal to identify environmental causes of T1D. This study was
performed according to the principles of the Declaration of Helsinki. Written informed con-
sent was obtained for all study participants from a parent or legal guardian. The TEDDY study
was approved by local Institutional Review Boards at 6 clinical research centers (3 in the United
States and 3 in Europe): University of Colorado Health Science Center, Georgia Regents Uni-
versity, Pacific Northwest Diabetes Research Institute, Turku University Hospital (Finland),
Institute of Diabetes Research (Germany), and Lund University (Sweden). The study is also
monitored by an external evaluation committee formed by the National Institutes of Health.
Assessment of tissue transglutaminase autoantibodies (tTGA)
Sera were measured for tTGA using radioligand binding assays in two laboratories, IgA-tTGA
assay at the Barbara Davis Center for Childhood Diabetes for the US samples and IgA-tTGA
and IgG-tTGA assay at the University of Bristol for European samples. All positive US samples
were also assayed by the Bristol lab. Levels of tTGA were expressed in arbitrary units derived
from a standard curve and were considered to be positive if the value was1.3 units. The
inter-assay coefficient of variation was 22% at both 6 units and 20 units.
Study outcomes
Persistent tTGA was defined as having two consecutive positive tTGA tests (as measured by
the Bristol laboratory) taken at least three months apart. Children meeting this criterion were
referred to a pediatric gastroenterologist for a clinical evaluation for celiac disease. Celiac dis-
ease was defined as having an intestinal biopsy showing a Marsh score of 2 or greater by origi-
nal Marsh criteria [41]. Children who had persistent tTGA with a mean level of>100 units in
two consecutive samples but had no intestinal biopsy data, were also considered as having
celiac disease for the purpose of this study [13].
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Single-nucleotide polymorphism (SNP) analysis by ImmunoChip
SNPs were genotyped by the Center for Public Health Genomics at University of Virginia,
using the Illumina ImmunoChip Infinium array. The ImmunoChip is a custom genotyping
array of 195,806 SNPs selected from 186 regions associated with 12 autoimmune diseases.
Genotype calling and quality control steps were applied to the dataset: (1) individuals with low
call rate (<95%), or discordance with reported gender and prior genotyping were not consid-
ered in the analysis, (2) SNP markers with low call rates (<95%) were excluded, and (3) mark-
ers with allele distributions strongly deviating from Hardy-Weinberg equilibrium (HWE) in
controls (p<10−6) were discarded (except for chromosome 6 due to HLA eligibility require-
ments). This resulted in a total of 7,023 subjects with genotype data on 176,586 SNPs.
Fig 5. Flow chart of study participants. The Environmental Determinants of Diabetes in the Young (TEDDY) is an international multicenter study that
screened over 420,000 newborns from the general population in four different countries. The present study genotyped 195,806 SNPs on ImmunoChip in
6,010 TEDDY children to identify potential genetic factors responsible for the development of CD and country-specific differences in genetic predisposition.
As shown in flow chart, a total of 6,010 subjects were included in the analysis of time-to-CD, and 5379 subjects were included in the analysis of time-to-tTGA.
doi:10.1371/journal.pone.0152476.g005
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Statistical analysis
The time-to-persistent tTGA and the time-to-celiac disease were the two primary outcomes
analysed in this study. The time-to-persistent tTGA was defined as the age when the sample
for the first tTGA positive test was collected, and the right-censored time was the age when the
participant’s last blood sample was collected for testing of tTGA. The time-to-celiac disease
was the child’s age at the time of biopsy for the diagnosis of celiac disease, or the age of the first
high-level tTGA result (defined as100 units). The right-censored time was the age of the last
TEDDY clinic visit that was confirmed to be celiac disease-free. Cox proportional hazards
modelling was used to analyse the effect of each individual SNP (by genotype 0,1,2) on the out-
come, after adjusting for country (as strata), gender, HLA-DPB1 genotype, HLA-DR-DQ geno-
type (e.g., DR3-DQ2/DR3-DQ2, DR3-DQ2/X, DR4-DQ8/DR4-DQ8 and Other), family
history (first-degree relative) of celiac disease, and principal components to account for popu-
lation stratification (ancestral heterogeneity). The Cox models were fitted using the “survival”
package in R [42]. The first four principal components were used in these analyses, calculated
from the SNP data using the SNPRelate software [43]. As the majority of the subjects were
Caucasians, and to reduce population stratification further, subjects from other races were
excluded and analyses were restricted to the 6,258 Caucasians from all six clinical centers.
Subject exclusion included those who had either an ineligible HLA genotype or unknown
family history (among first-degree relatives) of celiac disease. Further, subjects who did not
have tTGA tested were also excluded in the analysis of time-to-persistent tTGA. As a result,
6,010 subjects were included in the analysis of time-to- celiac disease, and 5,379 subjects were
included in the analysis of time-to- persistent tTGA (Fig 5). Among the 6,010 subjects included
in the analysis of celiac disease, the median follow-up time was 5 years (interquartile range:
3.75–6.44 years). Whereas, among the 5,379 subjects included in the analysis of persistent
tTGA, the median follow-up time was 5.18 years with an interquartile range of 4.04–6.54 years.
During the follow-up, a total of 703 subjects developed persistent tTGA (US: 191 out of 1785;
Finland: 167 out of 1414; Germany: 37 out of 328; Sweden: 308 out of 1852) and a total of 288
subjects were considered as having celiac disease (US: 83 out of 2028; Finland: 53 out of 1551;
Germany: 9 out of 399; Sweden: 143 out of 2032). The characteristics of TEDDY participants
in the analyses of persistent tTGA (S2 Table) and celiac disease (S3 Table) are provided in the
Supplementary material.
From the 176,586 SNPs that passed quality control filters, the analysis focused on those
133,620 with minor allele frequencies of at least 0.01; thus, statistical significance for any single
SNP required a Bonferoni-corrected p<3.7x10-7. This is a highly stringent threshold as a large
number of SNPs are in linkage disequilibrium which should reduce the total number of inde-
pendent tests. For the analyses of the 48 candidate SNPs that have been identified in previous
studies, we considered p<10−3 as suggestive evidence for confirmation (p = 0.05/48 = 10−3).
For the analyses of the 48 candidate regions, we considered p<10−4 as suggestive evidence for
confirmation as multiple SNPs are tested in each region and the SNPs are in high linkage
disequilibrium.
All analyses were performed using R 2.15.1. A web-based plotting tool locuszoom [44] was
used to plot HapMap CEU linkage disequilibrium r2 values for additional SNPs in the candi-
date SNP regions.
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